The Investment Dashboard provides a quick-access overview of neurodegenerative disease therapeutics investment landscape. This page serves as a central hub for navigating investment analysis, company profiles, funding trends, and therapeutic pipeline information across all disease areas. [1]
| Metric | Value |
|---|---|
| Total Investment Pages | 98 |
| Disease-Specific Landscapes | 11 |
| Mechanism-Specific Analyses | 30+ |
| Therapeutic Approach Pages | 40+ |
| Company Profiles | 200+ |
| Institutional Profiles | 225+ |
| Disease | Key Pages |
|---|---|
| Alzheimer's Disease | AD Investment Landscape, Amyloid Therapeutics, Anti-tau Therapeutics |
| Parkinson's Disease | PD Investment Landscape, Alpha-synuclein, LRRK2 Therapeutics |
| ALS | ALS Investment Landscape, Gene Therapy |
| Huntington's Disease | HD Investment Landscape |
| FTD | FTD Investment Landscape |
| Mechanism | Investment Page |
|---|---|
| Neuroinflammation | Neuroinflammation Therapeutics, NLRP3 Inflammasome |
| Protein Aggregation | Protein Aggregation Therapeutics, Tau Aggregation Inhibitors |
| Mitochondrial Dysfunction | Mitochondrial Therapeutics, Autophagy/Mitophagy |
| Metabolic Dysfunction | Insulin Signaling, AMPK Activators |
| Metal Ion Dysregulation | Metal Ion Dysregulation |
| Oxidative Stress | Oxidative Stress, NRF2 Therapeutics |
NeuroWiki Investment Section Overview. ↩︎